Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection

NCT01578785 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor.

NCT NCT01578785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01578785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2012
Completion date
November 30, 2012
Enrollment
178 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis